Novartis Ag

Other

Isis Pharmaceuticals, Inc.

Roger John Taylor

Robin Alec Fairhurst

David Andrew Sandham

Kamlesh Jagdis Bala

Neil John Press

Thomas Josef Troxler

Nichola Smith

Robert Alexander Pulz

Duncan Shaw

Mahbub Ahmed

David William Porter

Lisa Ann Rooney

James Dale

Anne-Marie Edwards

Andrew Brearley

Jessica Louise Taylor

Joe Wrigglesworth

Stephen Paul Collingwood

Clive McCarthy

Brian Cox

Anthony David Baxter

Thomas Hugo Keller

Alastair Denholm

Ian Bruce

Catherine Howsham

Lee Edwards

Simon James Watson

Bernard Cuenoud

Eric K Baylis

Emma Budd

David Beattie

Clive Mccarthy

Darren Mark Legrand

Katharine Louise Turner

Anne-Marie D'Souza

Mark Edward Douglas

Reamonn Madden

Michael Coward

Harinder Pal Singh

Anne-Marie D'souza

David Porter

Paul Singh

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Carboxamide derivatives

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

N-substituted heterocyclyl carboxamides

A compound of formula (I): in free or salt form, wherein A, R, R, Q, Qand Q are as defined herein, for the treatment of a disease mediated by the S1P2 or S1P3 receptor, such as inflammatory or obstructive airways disease. 

Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals 

Organic compounds

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, 

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U, U, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine Areceptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Adenosine derivatives as A2A receptor agonists

Compounds of formula I in free or salt form, wherein R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine Areceptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Purine derivatives for use as adenosine A-2A receptor agonists

Compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine Areceptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Purine derivatives as a2a agonists

Compounds of formula I in free or salt form, wherein &#x2014;C&#x2014;Y&#x2014;, Rand Rare G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the &#x3b2;-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Quinoline-2-one derivatives for the treatment of airways diseases

Compounds of formula I in free or salt form, wherein R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-&#x3b1; release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

[1,7]naphthyridines as PDE4 inhibitors

The invention relates to compounds of formula I in free or salt form, where Ris a monovalent aromatic group having up to 10 carbon atoms, and Ris a cycloaliphatic group having up to 8 ring carbon atoms. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.

Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors

Growing community of inventors

Horsham, United Kingdom

Roger John Taylor